Kornimate/medical-research-clean huggingface dataset:
a randomized incentive-based weight loss trial in singapore

Conditions: Obesity; Incentives

Summary: the purpose of this study is to test the extent to which incentives, when combined with an existing evidence-based weight loss program, improve weight loss and weight loss maintenance. it will also compare the cost-effectiveness of the incentive-based weight loss programs to the basic program without incentives.

globally, the rise in obesity rates has reached epidemic proportions, and in singapore 53% of adults have a body mass index (bmi) great than 23.0 kg/m2, a level that increases risk for chronic disease among asians. this study aims to test the extent to which traditional or behavioural economic incentives, when combined with an existing evidence-based weight loss program, improve weight loss and weight loss maintenance. data will be collected through a two-arm (basic weight loss program, basic program plus traditional or behavioural economic incentives) randomized controlled trial (rct) where key outcome variables are defined as weight loss (kilograms) at 8 months when the incentive program concludes, and at 12 months, after a 4 month period in which no additional incentives are provided. we hypothesize that at both 8 and 12 months, weight loss will be greater in the incentive arm than in the arm without incentives. the growing obesity epidemic, the high costs of obesity to employers, insurers and governments across asia, and the fact that the incentive program is designed to be close to cost neutral, suggest that this research has high potential to have a significant public health impact, both in singapore and the region.

Eligibility criteria:
inclusion criteria: * signed informed consent * age 21+ * bmi 25+ * willing to be randomized into 1 of the 2 study arms * willing to pay the $399 entry fee * stated willingness to commit to participating in all assessments regardless of weight change or study arm exclusion criteria: * current pregnancy/lactation (women who become pregnant during the study will be withdrawn) * type 1 diabetes * type 2 diabetes on medication other than metformin * end-stage renal disease * ischemic heart disease requiring intervention in the past 6 months * thyroid disease that has yet to stabilize * changes in weight of greater than 3% in the past 6 months * use of weight loss medication in the past 6 months * malignancy requiring chemotherapy/radiation in the past 5 years * acute medical problems requiring 3+ days of missed work during previous 4 week period * any serious hospitalization or surgery in the past 6 months * use of corticosteroids in the past 6 months * answer 'yes' to any of the par-q questions * unable to obtain md consent from a physician giving permission to participate in the study * evidence of clinical depression (as assessed by the beck depression inventory) * currently on medications for a mental health or substance abuse condition * evidence of binge eating based on the binge eating disorders scale (beds) * unable to communicate in english * additional concerns in which the clinical investigator deems problematic for participation

Keywords: obesity weight loss incentives motivation
the effect of sujok therapy on cancer symptoms

Conditions: Cancer

Summary: the aim of this study is to determine the effect of sujok therapy on pain, fatigue, insomnia, nausea and vomiting experienced by patients with gastrointestinal system cancer.

the aim of this study is to determine the effect of sujok treatment on pain, fatigue, insomnia, nausea and vomiting experienced by patients with gastrointestinal system cancer. intervention and control groups will be determined by randomization. the scales to be used in the measurement will be applied to the individuals included in the study. then, sujok therapy will be applied to the intervention group. after 6 sessions in weeks in total, measurement tools will be applied and evaluated again.

Eligibility criteria:
inclusion criteria: * over 18 years old * fatigue severity measurement - visual analogue scale (vas) fatigue score of 3 and above, * pain severity measurement - visual analogue scale (vas) pain score of 3 and above, * measurement of nausea and vomiting severity - patients with a visual analogue scale (vas) nausea and vomiting score of 3 and above will be included. exclusion criteria: * loss of sensation, amputation, injury, colostomy, etc., which will prevent practice in hands. patients will be excluded from the study.

Keywords: pain insomnia fatigue nausea and vomiting gastrointestinal system cancer. sujok therapy
a comparison of critical errors, overall errors, training/teaching time, and preference attributes of the ellipta versus breezhaler dry powder inhalers (dpis) in adult participants with asthma

Conditions: Asthma

Summary: this study aims to provide data in adult participants with mild to moderate asthma to assist healthcare professionals (hcps) in assessing various attributes of ellipta and breezhaler dpis, by comparing the incidence of critical and overall errors, participant preference, willingness to continue with the inhaler and time to correct use. ellipta® is a registered trademark of glaxosmithkline (gsk) and breezhaler® is a registered trademark of novartis.


Eligibility criteria:
inclusion criteria: * participants must be aged 18 years or older at the time of signing the informed consent. * participants who have a confirmed mild or moderate asthma diagnosis as per global initiative for asthma (gina), 2020. * participants must be on asthma maintenance therapy (inhaled corticosteroids \[ics\] or ics/ long acting beta 2-agonist \[laba\]) for at least 12 weeks prior to study participation. * participants must be naïve to both the ellipta and breezhaler inhalers. * females who are not pregnant or not planning a pregnancy during the study or not lactating. * capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol. exclusion criteria: * concurrent diagnosis of chronic obstructive pulmonary disease (copd) or other respiratory disorders. * history of hypersensitivity to any components of the study inhaler (e.g., lactose). in addition, participants with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates participation will also be excluded. * historical or current evidence of clinically significant or rapidly progressing or unstable disease that, in the opinion of the investigator, would put the safety of the participant at risk through participation, or which would affect the analysis if the disease/condition exacerbated during the study. * drug/alcohol abuse: participants with a known or suspected alcohol or drug abuse, which in the opinion of the investigator could interfere with the participant's proper completion of the protocol requirement. * a participant will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator, as well as employees of gsk or novartis. * inability to read: in the opinion of the investigator, any participant who is unable to read and/or would not be able to complete a questionnaire and understand verbal instructions. * medical and physical conditions that in the opinion of the investigator could impact the ability of the participant to manipulate the inhaler.

Keywords: ellipta breezhaler dry powder inhaler asthma
capsula closure vs. non-capsula closure: hip arthroscopy in danish patients with femoroacetabular impingement (fai)

Conditions: Hip Injuries

Summary: the purpose of this study is to investigate whether patients undergoing surgical treatment (hip arthroscopy) of fai syndrome will positively benefit from capsular closure, in terms of higher scores in validated patient reported outcome measurements, compared to a group of patients with fai syndrome where the capsule is left open at the end of the surgical procedure.


Eligibility criteria:
inclusion criteria: * radiological and symptomatic femoroacetabular impingement, where surgery is indicated. preoperatively a minimum of 3 months of relevant physiotherapeutic treatment should have been performed. exclusion criteria: * previous hip surgery in either hip * malignant disease * recent hip or pelvic fractures * arthritic disease * hip joint dysplasia * legg-calvé-perthes * slipped capital femoris epiphysis * recent (within 6 weeks) medical treatment with corticosteroids * language problems of any kind
a rehabilitation program in children with sickle cell disease and cognitive deficits: a pilot study

Conditions: Sickle Cell Disease

Summary: the overall goal of this project is to determine the feasibility of conducting a cognitive intervention for children with sickle cell disease.

the primary aims of this clinical trial are: 1. determine the effectiveness of targeted learning and memory strategy remediation in students with sickle cell disease and cognitive deficits. 2. determine if there is improvement in academic achievement after targeted memory strategy remediation.

Eligibility criteria:
inclusion criteria: * sickle cell disease that is confirmed by hemoglobin analysis * has a brain magnetic resonance imaging (mri) document reading by a neuroradiologist * cognitive deficits, which are defined by one standard deviation lower than the normal ranges of an age-based standard score in cognitive tests that are evaluated by a psychologist * must be a student who will remain in school for at least 2 years * must provide informed consent with assent in accordance with the institutional policies (institutional review board approval) exclusion criteria: * known developmental delays (these participants are ineligible because their learning potential may be biased from a prior insult) * intelligent quotient is less than 50 (may have impaired learning potential) * aphasic (i.e., unable to produce intelligible speech)

Keywords: sickle cell disease sickle cell memory learning achievement
step into support for endurance and strength (sisters)

Conditions: Gynecologic Cancer

Summary: the step into support for endurance and strength (sisters) research study is evaluating whether a mobile health game designed to increase physical activity is feasible and acceptable in patients with gynecologic cancers. -sisters is testing a mobile health intervention can help increase physical activity. participants will be randomized to receive either 1) a fitbit or 2) a fitbit + a game + help from a friend or family member whom you chose will help the participant reach their goals. (i.e. a teammate).

this study is a two-arm randomized controlled pilot study designed to test the feasibility and acceptability of using a wearable accelerometer (fitbit) vs. a wearable accelerometer (fitbit) + a game designed to help participants increase physical activity + social support improves participants' average daily step counts. eligible participants will be randomly assigned into 1 of 2 groups 1. fitbit (wearable accelerometer) or 2. fitbit (wearable accelerometer) + game + help from a self-selected teammate the study interventions involved in this research are: * surveys/interviews * fitbits (also known as a wearable accelerometers or fitness trackers) * way to health platform * help from a teammate (i.e. a friend or family member that participants choose to help them reach their goals) it is expected that about 50 people will take part in this research study.

Eligibility criteria:
inclusion criteria: * patients ≥18 years of age with a gynecologic cancer (ovarian, fallopian tube, primary peritoneal carcinoma, uterine, or cervical) who have completed cancer treatment ≥ 6 weeks prior. * own a smartphone (android or ios). * can read and provide informed consent in english. * do not have cognitive, visual, or orthopedic impairments that preclude participation, as evaluated by the research staff or oncology provider. * insufficiently active, as indicated by a score of \<14 on the leisure score index of godin leisure-time exercise questionnaire (lsi). * no future chemotherapy planned (except maintenance treatments; e.g. parp inhibitors or endocrine therapy) exclusion criteria: * patients already participating in a mobile health intervention. * patients who do not own a smartphone or computer to transmit data from the wearable tracker. * self-reported inability to walk 2 blocks (at any pace). * patients who are unable to identify a social support partner (i.e. family member, friend, or partner) to participate in the study (if selected for the intervention arm). * the following special populations will be excluded from this research: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners

Keywords: gynecologic cancer mobile health fitness tracker survivorship quality of life physical activity feasibility study pilot
aging with dignity, health, optimism and community

Conditions: HIV

Summary: adhoc is an observational study of people living with hiv over the age of 50. data from this study will be used to research the interaction between hiv and aging.

adhoc is an observational study that collects data on plwh over the age of 50 using an online questionnaire. the questionnaire includes information on sociodemographic factors, activities and interests, hiv diagnosis and status, health care use and satisfaction, antiretroviral therapy, comorbid medical conditions, health and well-being, substance use, and sexual practices.

Eligibility criteria:
eligibility criteria: * have an hiv-1 or -2 infection, * be ≥ 50 years of age, * have no known acute medical problems requiring immediate inpatient treatment, * be able to read and write in english, and * be able and willing to provide online informed consent and complete the profile online.

Keywords: hiv plwh aging older
diagnostic assessment of 18f-fluciclovine and 18f-fdg -pet/mri of primary central nervous system lymphoma

Conditions: Lymphoma, Non-Hodgkin; Central Nervous System Neoplasms

Summary: primary central nervous system lymphoma (pcnsl) is a rare subtype of extranodal non-hodgkins lymphoma (nhl) with rising incidence and variable response to treatment. mri is considered the most useful imaging modality of pcnsl, but conventional mri has its limitations, and contrast-enhanced mri sometimes does not clearly differentiate pcnsl from other neoplasm or non-neoplastic diseases. positron emission tomography (pet) could have a number of potential advantages in refining and improving the management of patients with pcnsl. because of the rare incidence of pcnsl, the value of pet has however not been well defined in this subtype of lymphomas. there are a few studies that have investigated the role for fdg-pet and amino acid pet in the primary staging/diagnosis and response assessment in pcnsl patients, but the results are inconclusive. further studies are therefore needed. previous studies support an integration of both mri and pet for the routine diagnostic workup and response assessment for pcnsl, and the newly available simultaneous pet/mri scanners may have the potential to improve imaging baseline accuracy, response assessment and add prognostic value in pcnsl. the main aim of the study is to compare the sensitivity and specificity of a combined pet/mri examination with the clinical routine mri examination given to these patients today. it will be investigated whether pet (18f-fdg and 18f-fluciclovine) can provide additional prognostic value at baseline and in response assessment compared to mri and established pre-treatment prognostic scores in pcnsl, and evaluate which pet/mri parameters that are best suited as an imaging biomarker for progression-free survival.


Eligibility criteria:
inclusion criteria: * histological diagnosis of pcnsl based on cytology/flow cytometry of cerebrospinal fluid (csf) or brain biopsy * written informed consent from patient or guardian * immunocompetent exclusion criteria: * previous chemotherapy * contra-indications for mri (pacemakers, defibrillators, aneurysm clips, any form of metal in the body, or severe claustrophobia) * hypersensitivity to either 18f-fluciclovine or 18f-fdg or to any of the excipients * pregnancy (pregnancy test for all women in fertile age) * breastfeeding * weight \> 120 kg * estimated glomerular filtration rate (egfr) \<30ml/min/1,73m2 * hiv-positive

Keywords: positron-emission tomography magnetic resonance imaging
the effect of hypovitaminosis d and vitamin d supplementation on fracture nonunion rates

Conditions: Hypovitaminosis D

Summary: the purpose of the study is to determine whether vitamin d supplementation in patients with hypovitaminosis d can decrease nonunion (failure to heal) incidence in patients with fractures of the humerus, femur, or tibia. the central hypothesis of the study is that vitamin d supplementation in patients with fractures and hypovitaminosis d will decrease the risk of nonunion compared to placebo treatment.

vitamin d plays an important role in maintaining calcium and phosphate balance in the body and is important for maintenance of bone formation, remodeling, and healing. an extensive literature search indicates that although there is evidence that vitamin d deficiency is associated with fracture risk, there is no evidence of the role of vitamin d deficiency in subsequent failure to heal. the aims of study were to: 1) quantify the rate of hypovitaminosis d in an orthopedic trauma population in the southeastern united states; 2) determine the rate of nonunion in vitamin d deficient patients, and 3) assess the feasibility of acute high-dose vitamin-d supplementation in hypovitaminosis d patients.

Eligibility criteria:
inclusion criteria: * presence of a long bone fracture (humerus, femur, or tibia) * age greater than or equal to 18 years * ability to follow-up at our clinic for 12 months exclusion criteria: * pathologic fractures (i.e. occuring in the presence of abnormal bone such as a tumor, cyst, or paget's disease) * open fractures (i.e. associated skin disruption) of gustilo-anderson type iiib or c (i.e. significant soft-tissue and bone devitalization) * presence of multiple fractures * delay in presentation for initial treatment of more than 2 weeks from the time of injury * preexisting disorders known to adversely affect bone healing (e.g. diabetes mellitus with hba1c greater than or equal to 7, peripheral vascular disease, certain connective tissue disorders, and congenital or acquired disorders of bone metabolism) * preexisting disorders affecting vitamin d metabolism and/or calcium phosphate homeostasis (e.g. renal failure, hepatic failure, congenital defects in vitamin d metabolism, parathyroid disorders, conditions causing abnormal calcium and/or phosphate absorption) * pregnant patients * patients who are unable to provide consent for the study * patients who are unable to swallow due to acuity of illness or physiologic reason * prisoners who are patients because of their vulnerable population and inability to follow-up

Keywords: vitamin d nonunion long bone fracture hypovitaminosis d
the sweet pea study: effects of diet during pregnancy on infant growth and development.

Conditions: Obesity

Summary: the purpose of the sweet pea study is to determine whether diet during pregnancy has an effect on infant's growth, body composition, and brain development.

rationale: non-nutritive sweetener (nns) consumption during pregnancy is prevalent, but effects on maternal and infant health are not well known. intervention: none objectives: to determine whether nns consumption during pregnancy is associated with increased infant body fat, as well as differences in infant growth, brain structure/function, gut microbiota, and gestational diabetes. study population: women prior to 28 weeks' gestation, determined to have either low/no nns consumption (control) or high nns consumption (experimental), based on a pre-screening survey. methodology: identify two groups (low/high consumers) in early pregnancy, collect data during pregnancy remotely (telephone, internet, medical records) to determine diet and any link to pregnancy complications, have in-person visits with mothers/infants at 1, 6, and 12 months of age, collecting: body composition data (by echomri), brain structure/connectivity (mri), stool samples. outcomes: primary outcome is infant adiposity at 1, 6, and 12 months. additional measures include infant growth, feeding behaviors, brain structure/ connectivity, gut microbiota, and maternal metabolic outcomes during routine gestational testing (fasting glucose, insulin, triglycerides, gestational diabetes diagnosis) follow-up: this will operate as a small pilot study, and a larger study with more participants, a wider spectrum of nns exposure, and longer follow up (into childhood and beyond) may follow. statistics: multivariate linear mixed effects examining maternal nns intake and outcomes across time (repeated measures)

Eligibility criteria:
inclusion criteria: mothers: * pregnant women prior to 28 weeks gestation * report the least nns consumption of pre-screened participants (0 servings per week - representing the control group) and most nns consumption of pre-screened participants (≥ 5 servings per week - representing the experimental group). * 18-40 years of age * singleton pregnancy * be able/willing to understand the procedures of the study * be able to read english at a 5th grade level (materials also available in spanish, if required) infants: * infant's mother must be enrolled in the study and provide infant assent to participate exclusion criteria: mothers: * physician diagnosis of a major medical illness * pre-existing diabetes (type 1 or type 2), or gdm in a previous pregnancy * physical, mental, or cognitive issues preventing participation * medications that may affect body weight, body composition, insulin resistance, or lipid profiles * tobacco or drug use (any current use or quitting during pregnancy) * alcohol consumption during pregnancy (\>1 drink per week) infants: * presumed or known congenital birth defects

Keywords: pregnancy nutrition obesity mother infant cognitive development growth